Skip to content

Does hs-CRP predict the severity of cardiovascular disease and chronic kidney disease?

Association of high sensitivity C-reactive protein in an established atherosclerotic cardiovascular disease with chronic kidney disease: A prospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/03/050262
Enrollment
854
Registered
2023-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I702- Atherosclerosis of native arteriesof the extremities Health Condition 2: I251- Atherosclerotic heart disease of native coronary artery Health Condition 3: I639- Cerebral infarction, unspecified Health Condition 4: N189- Chronic kidney disease, unspecified

Interventions

None listed

Sponsors

MANIPAL ACADEMY OF HIGHER EDUCATION
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Evidence of ASCVD and CKD stage 3 or stage 4

Exclusion criteria

Exclusion criteria: Clinical evidence of, or suspicion of active infection, myocardial infarction, stroke, hospitalization for unstable angina pectoris, or transient ischemic attack within 30 days prior to recruitment Planned coronary, carotid, or peripheral artery revascularization known on the day of screening Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 30 days prior to recruitment or any major surgical procedure planned at the time of recruitment hsCRP levels of more than 20 are excluded and reassessed later about including patients in the study

Design outcomes

Primary

MeasureTime frame
Prevalence of elevated hs-CRP levels in established ASCVD and CKD Identifying the relationship between raised levels of hs-CRP and other biochemical parameters among the sub-group population with established ASCVD Timepoint: at the time of collection

Secondary

MeasureTime frame
Identifying the association of clinical and physical parameters with hs-CRP levels in patients with established ASCVD Co-relation between hs-CRP and MACE rate on total 12 months, follow-up of patients with documented ASCVD on standard medical therapy Adverse renal events Timepoint: 12 months

Countries

India

Contacts

Public ContactDr Tom Devasia

Kasturba Medical College and hospital, Manipal

drtomdev22@gmail.com9448158508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026